Summary & Overview

HCPCS Q3028: Injection, interferon beta-1a, 1 mcg subcutaneous

HCPCS Level II code Q3028 designates a 1 microgram subcutaneous injection of interferon beta-1a, a disease-modifying agent commonly used in multiple sclerosis management. Nationally, accurate reporting of this HCPCS Level II code matters for clinical documentation, claims adjudication, and tracking utilization of specialty injectable therapies.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical context and typical sites of service, followed by analyses relevant to billing and coverage patterns. The publication outlines what audiences can expect: benchmark metrics for utilization and reimbursement (where applicable), common billing considerations, and any notable policy or coverage updates affecting injectable disease-modifying therapies.

This summary provides clinical and billing stakeholders with the essential facts needed to recognize when to report HCPCS Level II code Q3028, understand its role in claims, and identify areas where payer rules and documentation expectations commonly intersect. Data not provided in the input—such as specific payer rates, associated ICD-10 diagnoses, and related codes—is noted as unavailable for this release.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareQ3028HCPCS Level IIinterferon beta-1asubcutaneous injectiondrug administrationspecialty injectablemultiple sclerosisbilling

Billing Code Overview

HCPCS Level II code Q3028 represents Injection, interferon beta-1a, 1 mcg for subcutaneous use. This code is used to report the administration of a one microgram dose of interferon beta-1a formulated for subcutaneous injection.

Service type: Drug administration (subcutaneous injection)

Typical site of service: Outpatient clinic, physician office, or other ambulatory care setting where subcutaneous injections are administered.

Clinical & Coding Specifications

Clinical Context

A 38-year-old woman with relapsing-remitting multiple sclerosis attends a neurology clinic for her scheduled subcutaneous disease-modifying therapy. The clinician documents the indication, reviews recent labs and infection risk, confirms no contraindications, and verifies patient training for self-administration. The clinic prepares and administers a 1 mcg subcutaneous injection of interferon beta-1a (billing code Q3028) when the patient requests clinic administration rather than self-injection at home. The workflow includes: medication verification and consent, medication preparation and documentation in the medication administration record, administration of the subcutaneous injection, observation for immediate adverse reactions (typically 15–30 minutes), documentation of lot number and injection site, and scheduling of the next dose with counseling regarding flu-like adverse effects and when to seek care. Typical site of service is an outpatient infusion or clinic procedure room, neurology office, or a specialty clinic where injectable disease-modifying therapies are administered and billable under HCPCS Level II code Q3028. Common payors for authorization and claims adjudication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.

Coding Specifications

Modifier	Description	When to Use
`00`	Unmodified or no modifier	When no special circumstances apply to the service.
`22`	Increased procedural services	When documentation supports substantially greater work than typical for the injected drug administration.
`23`	Unusual anesthesia	Rarely used for subcutaneous injection; only if unusual anesthesia was required and documented.
`52`	Reduced services	When the injection or visit was partially reduced or not completed as originally planned.
`53`	Discontinued procedure	When administration was started but halted due to patient intolerance or emergent condition before completion.
`62`	Two surgeons	Not commonly applicable; used only if two providers from different specialties shared responsibility for the procedure.
`78`	Return to operating room for a related procedure	Not typical for `Q3028`; applicable if a related subsequent operative procedure occurs during the same global period.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery	Generally not applicable to routine subcutaneous injection; included if advanced practice provider performed the service per payor rules.
`QX`	Service furnished by a physician assistant with medical direction by a physician when modifier `QK` not reported	Used when a physician assistant performs the injection under appropriate supervision as defined by payor.
`QK`	Medical direction of two, three, or four concurrent anesthesia procedures	Rare for this code; included only if applicable anesthesia medical direction rules apply.
`QY`	Medical direction of one certified registered nurse anesthetist (CRNA) by an anesthesiologist	Rarely applicable; listed for completeness when anesthesia direction rules impact billing.
`SH`	Physician is clinical staff providing services at a facility-owned clinic	Used when the physician is clinic staff and facility billing rules require this modifier.
`SJ`	Alternative payment for services incident to a physician in an outpatient setting	Applicable when billing rules for incident-to services require this modifier for non-physician clinicians administering the injection.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Neurology	Neurologists frequently prescribe and supervise interferon beta-1a therapy.
`363L00000X`	Pharmacy	Clinic or specialty pharmacists prepare and verify injectables in some settings.
`364S00000X`	Nurse Practitioner	NPs commonly administer or supervise administration of subcutaneous DMTs.
`163W00000X`	Physician Assistant	PAs frequently perform injections and clinic follow-up for MS therapies.
`253E00000X`	Registered Nurse	RNs typically perform medication administration and patient observation in clinic.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G35`	Multiple sclerosis	Primary indication for interferon beta-1a therapy; used to reduce relapse frequency and delay disability progression.
`G36.0`	Neuromyelitis optica	Some demyelinating disorders may prompt consideration of disease-modifying therapies; clinical correlation required.
`G37.9`	Demyelinating disease of central nervous system, unspecified	Situations where a specific demyelinating diagnosis is pending but injectable immunomodulatory therapy is being considered.
`D61.9`	Aplastic anemia, unspecified	Included as a monitoring consideration when bone marrow suppression or hematologic adverse effects must be evaluated before therapy.
`Z79.899`	Other long term (current) drug therapy	Indicates ongoing long-term therapy with disease-modifying agents such as interferon beta-1a.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Commonly billed when a clinician administers a single subcutaneous injection in the office; may be used in conjunction with HCPCS `Q3028` depending on payor rules.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Typical accompanying E/M level for routine follow-up visits when administering maintenance injections and counseling the patient.
`99070`	Supplies and materials (e.g., local protective items) provided by the physician over and above those usually included with the office visit	Use for additional disposable supplies required for injection administration when payor allows.
`96360`	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	Not directly used for subcutaneous injection but listed for workflows where infusion or observation services are required in addition to injection.
`96374`	Therapeutic, prophylactic, or diagnostic injection; each additional sequential intravenous push of same drug (List separately in addition to primary procedure)	Rarely applicable to single-dose subcutaneous injections; included when multiple injections are administered sequentially in the same encounter.